BioScrip (NASDAQ:BIOS) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Thursday.

A number of other equities research analysts have also commented on BIOS. SunTrust Banks restated a “buy” rating and set a $3.00 price objective on shares of BioScrip in a report on Friday, November 3rd. Zacks Investment Research lowered shares of BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, ValuEngine upgraded shares of BioScrip from a “strong sell” rating to a “sell” rating in a report on Thursday, November 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $3.63.

Shares of BioScrip (NASDAQ:BIOS) opened at $3.00 on Thursday. BioScrip has a twelve month low of $1.21 and a twelve month high of $3.39. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11.

BioScrip (NASDAQ:BIOS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The company had revenue of $198.70 million for the quarter, compared to analyst estimates of $202.91 million. During the same quarter last year, the firm posted ($0.12) EPS. The firm’s revenue for the quarter was down 11.5% compared to the same quarter last year. equities analysts expect that BioScrip will post -0.63 earnings per share for the current year.

In related news, CEO Daniel E. Greenleaf acquired 15,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The shares were acquired at an average cost of $2.03 per share, for a total transaction of $30,450.00. Following the completion of the acquisition, the chief executive officer now directly owns 31,000 shares in the company, valued at approximately $62,930. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.80% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd acquired a new stake in BioScrip in the 3rd quarter valued at $114,000. Captrust Financial Advisors acquired a new stake in BioScrip in the 2nd quarter valued at $123,000. Voya Investment Management LLC increased its stake in BioScrip by 41.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock valued at $138,000 after buying an additional 14,867 shares during the last quarter. Highbridge Capital Management LLC acquired a new stake in BioScrip in the 3rd quarter valued at $153,000. Finally, Skylands Capital LLC acquired a new stake in BioScrip in the 3rd quarter valued at $272,000. Hedge funds and other institutional investors own 84.63% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “BioScrip (BIOS) Rating Increased to Buy at BidaskClub” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2018/01/06/bioscrip-bios-rating-increased-to-buy-at-bidaskclub.html.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Stock Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related stocks with our FREE daily email newsletter.